Trump's Corporate Tax Holiday Could Spur Pharma M&A

Trump's Corporate Tax Holiday Could Spur Pharma M&A


U.S. President-elect Donald Trump's plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth. For years, big U.S. drugmakers have turned to acquisitions of foreign companies to put their overseas cash to work, rather than bring it home at a 35-percent tax rate.



from Biotech News